The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
A New Polymer–Lipid Hybrid Nanoparticle System Increases Cytotoxicity of Doxorubicin Against Multidrug-Resistant Human Breast Cancer Cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Solid lipid nanoparticles (SLN) for controlled drug delivery â a review of the state of the art
Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,759
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“One of the most studied cellular mechanisms is the classical form of multidrug resistance (MDR), which is usually mediated by the overexpression of P-glycoprotein (Pgp) and other membrane transporters (3).”
BackgroundFocan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Pluronic® block copolymers for overcoming drug resistance in cancer
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00047-9 · Cited by 636
Tannock, I. F., Hill, R. P., & Carey, R. W. (1989) · Plastic and Reconstructive surgery · doi:10.1097/00006534-198905000-00037 · Cited by 473
Kreuter, J., Ramge, P., Petrov, V., Hamm, S., Gelperina, S. E., Engelhardt, B., Alyautdin, R., von Briesen, H., & Begley, D. J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022604120952 · Cited by 469
The production and characteristics of solid lipid nanoparticles (SLNs)
Hou, D., Xie, C., Huang, K., & Zhu, C. (2003) · Biomaterials · doi:10.1016/s0142-9612(02)00578-1 · Cited by 437
Chemotherapy of glioblastoma in rats using doxorubicin‐loaded nanoparticles
Steiniger, S. C. J., Kreuter, J., Khalansky, A. S., Skidan, I. N., Bobruskin, A. I., Smirnova, Z. S., Severin, S. E., Uhl, R., Kock, M., Geiger, K. D., et al. (2004) · International Journal of Cancer · doi:10.1002/ijc.20048 · Cited by 434
Howell, A., Ribeiro, G. G., & Swindell, R. (1995) · Cited by 410
Paclitaxel nanoparticles for the potential treatment of brain tumors
Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.006 · Cited by 299
Batrakova, E., Lee, S., Li, S., Venne, A., Alakhov, V., & Kabanov, A. (1999) · Pharmaceutical Research · doi:10.1023/a:1018942823676 · Cited by 289
Emilienne Soma, C., Dubernet, C., Bentolila, D., Benita, S., & Couvreur, P. (2000) · Biomaterials · doi:10.1016/s0142-9612(99)00125-8 · Cited by 281
Cytotoxicity of Solid Lipid Nanoparticles as a Function of the Lipid Matrix and the Surfactant
Müller, R. H., Rühl, D., Runge, S., Schulze-Forster, K., & Mehnert, W. (1997) · Pharmaceutical Research · doi:10.1023/a:1012043315093 · Cited by 265
ATP binding cassette transporters and drug resistance in breast cancer.
Leonessa, F., & Clarke, R. (2003) · Endocrine-related cancer · doi:10.1677/erc.0.0100043 · Cited by 259
(1999) · Oncology · doi:10.1093/oso/9780192629784.003.0001 · Cited by 244
Romsicki, Y., & Sharom, F. J. (1999) · Biochemistry · doi:10.1021/bi990064q · Cited by 235
Fenart, L., Casanova, A., Dehouck, B., Duhem, C., Slupek, S., Cecchelli, R., & Betbeder, D. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35204-8 · Cited by 196
Koukourakis, M. I., Koukouraki, S., Fezoulidis, I., Kelekis, N., Kyrias, G., Archimandritis, S., & Karkavitsas, N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1459 · Cited by 186
Gelperina, S. E., Khalansky, A. S., Skidan, I. N., Smirnova, Z. S., Bobruskin, A. I., Severin, S. E., Turowski, B., Zanella, F. E., & Kreuter, J. (2002) · Toxicology Letters · doi:10.1016/s0378-4274(01)00456-8 · Cited by 185
Miglietta, A., Cavalli, R., Bocca, C., Gabriel, L., & Rosa Gasco, M. (2000) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(00)00562-7 · Cited by 180
Wong, H. L., Bendayan, R., Rauth, A. M., & Wu, X. Y. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20100 · Cited by 178
Self-citationLiposome-based approaches to overcome anticancer drug resistance
Mamot, C., Drummond, D. C., Hong, K., Kirpotin, D. B., & Park, J. W. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00082-7 · Cited by 170
de Verdière, A., Dubernet, C., Némati, F., Soma, E., Appel, M., Ferté, J., Bernard, S., Puisieux, F., & Couvreur, P. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.362 · Cited by 168
Serpe, L., Catalano, M. G., Cavalli, R., Ugazio, E., Bosco, O., Canaparo, R., Muntoni, E., Frairia, R., Gasco, M. R., Eandi, M., et al. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.03.026 · Cited by 165
Handbook of cancer chemotherapy
(1993) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(93)90321-b · Cited by 158
Abrahamse, S. L., Pool-Zobel, B. L., & Rechkemmer, G. (1999) · Carcinogenesis · doi:10.1093/carcin/20.4.629 · Cited by 135
By-passing of P-glycoprotein Using Immunoliposomes
Huwyler, J., Cerletti, A., Fricker, G., Eberlé, A. N., & Drewe, J. (2002) · Journal of drug targeting · doi:10.1080/10611860290007559 · Cited by 125
Handbook of cancer chemotherapy
Griffiths, M. (1996) · European Journal of Cancer Part B Oral Oncology · doi:10.1016/s0964-1955(96)90004-4 · Cited by 120
Modulation of doxorubicin resistance in multidrug‐resistant cells by liposomes
Thierry, A. R., Vigé, D., Coughlin, S. S., Belli, J. A., Dritschilo, A., & Rahman, A. (1993) · The FASEB Journal · doi:10.1096/fasebj.7.6.8097173 · Cited by 105
Liposomal formulations of anticancer drugs: selectivity and effectiveness
Massing, U., & Fuxius, S. (2000) · Drug Resistance Updates · doi:10.1054/drup.2000.0138 · Cited by 104
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer
Leonessa, F., Green, D., Licht, T., Wright, A., Wingate-Legette, K., Lippman, J., Gottesman, M., & Clarke, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.29 · Cited by 102
Soma, C. E., Dubernet, C., BARRATT, G. M., Némati, F., Appel, M., Benita, S., & Couvreur, P. (1999) · Pharmaceutical Research · doi:10.1023/a:1018902031370 · Cited by 78
Lo, Y. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00451-2 · Cited by 63
Liu, Z., Wu, X. Y., & Bendayan, R. (1999) · Journal of Pharmaceutical Sciences · doi:10.1021/js9803353 · Cited by 59
Self-citationIn vitro studies of the interaction of poly(NIPAm/MAA) nanoparticles with proteins and cells
Moselhy, J., Wu, X. Y., Nicholov, R., & Kodaria, K. (2000) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856200743616 · Cited by 59
Self-citationStudy of suboptimum treatment response: lessons from breast cancer
Lønning, P. E. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01022-2 · Cited by 57
Liu, Z., Ballinger, J. R., Rauth, A. M., Bendayan, R., & Wu, X. Y. (2003) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357021567 · Cited by 54
Self-citationTang, A., Kopečková, P., & Kopec̆ek, J. (2003) · Pharmaceutical Research · doi:10.1023/a:1022639701388 · Cited by 45
Chung, H. C., Rha, S. Y., Kim, J. H., Roh, J. K., Min, J. S., Lee, K. S., Kim, B., & Lee, K. B. (1997) · Breast Cancer Research and Treatment · doi:10.1023/a:1005739525196 · Cited by 44
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Solid lipid nanoparticles: A modern formulation approach in drug delivery system
Mukherjee, S., Ray, S., & Thakur, R. (2009) · Indian Journal of Pharmaceutical Sciences · doi:10.4103/0250-474x.57282 · Cited by 1,000
Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles☆
WONG, H., BENDAYAN, R., RAUTH, A., LI, Y., & WU, X. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.008 · Cited by 578
Self-citationNanoparticles: Emerging carriers for drug delivery
Mudshinge, S. R., Deore, A. B., Patil, S., & Bhalgat, C. M. (2011) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2011.04.001 · Cited by 543
Nanomaterials for Neural Interfaces
Kotov, N. A., Winter, J. O., Clements, I. P., Jan, E., Timko, B. P., Campidelli, S., Pathak, S., Mazzatenta, A., Lieber, C. M., Prato, M., et al. (2009) · Advanced Materials · doi:10.1002/adma.200801984 · Cited by 504
Metadata
- Authors
- Wong, H. L., Rauth, A. M., Bendayan, R., Manias, J. L., Ramaswamy, M., Liu, Z., Erhan, S. Z., & Wu, X. Y.
- Venue
- Pharmaceutical Research
- Published
- 2006-06-24
- Volume
- 23
- Issue
- 7
- Pages
- 1574-1585
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2012192443
- Cited by
- 303
- References
- 40
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.